Decision spine
Frames the controlling thesis, evidence status, buyer implications, and research-use limits.
Oncology
Zemi Dossier
Research-use only
MRD-Guided Neoantigen Vaccines
A decision package on whether minimal residual disease can route personalized neoantigen vaccines toward recurrence-prevention decisions.
Decision this dossier helps answer
Which MRD-guided vaccine strategies have enough timing, manufacturing, immune-response, and endpoint logic to justify next-step validation?
Problem this dossier solves
The vaccine decision starts with the residual-disease clock.
The dossier evaluates neoantigen vaccines through the timing and evidence constraints of recurrence prevention. It asks whether MRD signal, antigen choice, manufacturing time, and immune response can align before the recurrence window closes.
What is moving: current field evidence and platform activity
What is unresolved: decision-grade proof, endpoint logic, and failure modes
What Zemi solves: evidence-gated next-study strategy
Full decision package
115-page research report plus 37-sheet Evidence & Decision Workbook
Buy now
$3,500$5,500Launch price
Controlling thesis
The vaccine decision starts with the residual-disease clock.
The dossier evaluates neoantigen vaccines through the timing and evidence constraints of recurrence prevention. It asks whether MRD signal, antigen choice, manufacturing time, and immune response can align before the recurrence window closes.
A Zemi Dossier turns uncertain emerging research into a decision package: what is known, what is inferred, what is hypothetical, what would falsify the thesis, and what should be built, funded, avoided, monitored, or validated next.
Research report preview
First 30 pages of the actual MRD-Guided Neoantigen Vaccines research report.
The public page shows the real document style, density, evidence posture, and decision framing before a buyer requests access to the full Zemi Dossier package.
Research report
The research report is the argument. It is not the whole product.
The PDF research report is the structured argument: field status, evidence maturity, buyer implications, falsifiable hypotheses, power-calculated next studies, strategic recommendations, limitations, and traceability posture.
Inspectable infrastructure
Pairs the report with claim ledgers, evidence tables, power rows, audit surfaces, and decision tools.
Executable next studies
Links hypotheses to endpoint logic, assumptions, sample-size logic, budget, and timeline planning.
Research report table of contents
Public TOC generated from the source report.
The full research report is delivered as a licensed PDF. This table shows the decision structure without publishing the full product.
| Section | What it covers | Buyer value |
|---|---|---|
| Executive Summary | Condenses the dossier thesis, evidence posture, buyer implications, and next-study priorities. | Helps the buyer inspect the argument, evidence posture, and decision logic before relying on the package. |
| Decision Brief Read This First | Turns the report into immediate buyer triage: what matters now, what is still uncertain, and what to do next. | Helps the buyer inspect the argument, evidence posture, and decision logic before relying on the package. |
| Scope and Evidence Integrity | Defines the evidence window, source boundaries, research-use limits, and labeling discipline. | Lets the buyer audit support strength before relying on the package. |
| Denominator Definitions | Defines the populations, measurements, or comparison bases needed to interpret evidence without overgeneralizing. | Helps the buyer inspect the argument, evidence posture, and decision logic before relying on the package. |
| Current Signal Refresh | Frames the field's June 2026 state, active programs, research fronts, and timing signals. | Helps the buyer inspect the argument, evidence posture, and decision logic before relying on the package. |
| Decision Snapshot Overview | Maps findings to buyer actions: build, fund, avoid, monitor, or validate next. | Helps the buyer inspect the argument, evidence posture, and decision logic before relying on the package. |
| Buy Build Wait Avoid | Maps findings to buyer actions: build, fund, avoid, monitor, or validate next. | Helps the buyer inspect the argument, evidence posture, and decision logic before relying on the package. |
| Buyer Decision Cheat Sheet | Maps findings to buyer actions: build, fund, avoid, monitor, or validate next. | Helps the buyer inspect the argument, evidence posture, and decision logic before relying on the package. |
| Source Quality Dashboard | Shows how strong the source base is and where conclusions depend on indirect or thinner support. | Lets the buyer audit support strength before relying on the package. |
| Methodology and Search Strategy | Shows how strong the source base is and where conclusions depend on indirect or thinner support. | Helps the buyer inspect the argument, evidence posture, and decision logic before relying on the package. |
| The Five Axis Translation Model | Defines the governing argument and the evidence gates that would support or falsify it. | Helps the buyer inspect the argument, evidence posture, and decision logic before relying on the package. |
| The Interception Window Model | Defines the governing argument and the evidence gates that would support or falsify it. | Helps the buyer inspect the argument, evidence posture, and decision logic before relying on the package. |
| Interception Fitness Index | Operationalizes the thesis as a reusable decision surface for comparing programs or evidence states. | Gives the buyer a reusable way to compare programs, risks, and evidence states. |
| Interception Fit Classifier | Operationalizes the thesis as a reusable decision surface for comparing programs or evidence states. | Gives the buyer a reusable way to compare programs, risks, and evidence states. |
| Cross Tumor Convergence Map | Shows how separate research signals converge, diverge, or interact across domains, mechanisms, or study layers. | Helps the buyer inspect the argument, evidence posture, and decision logic before relying on the package. |
| Evidence Maturity Matrix and Platform Comparison | Links claims to source support so users can separate what is known, inferred, and hypothetical. | Gives the buyer a reusable way to compare programs, risks, and evidence states. |
| Competitive Landscape | Frames the field's June 2026 state, active programs, research fronts, and timing signals. | Connects research claims to practical diligence and monitoring decisions. |
| Key Findings | Summarizes the most decision-relevant findings and their implications for the dossier thesis. | Helps the buyer inspect the argument, evidence posture, and decision logic before relying on the package. |
| Detection / Trigger | Summarizes a report component that ties field evidence to the dossier's decision logic. | Helps the buyer inspect the argument, evidence posture, and decision logic before relying on the package. |
| Target Quality | Summarizes a report component that ties field evidence to the dossier's decision logic. | Lets the buyer audit support strength before relying on the package. |
| Immune Response / TME | Summarizes a report component that ties field evidence to the dossier's decision logic. | Helps the buyer inspect the argument, evidence posture, and decision logic before relying on the package. |
| Manufacturing & Time-to-Treat | Identifies translational, regulatory, safety, or delivery constraints that shape whether the thesis can be tested. | Helps the buyer inspect the argument, evidence posture, and decision logic before relying on the package. |
| Evidentiary Standard | Shows how strong the source base is and where conclusions depend on indirect or thinner support. | Helps the buyer inspect the argument, evidence posture, and decision logic before relying on the package. |
| Quantitative Evidence | Links claims to source support so users can separate what is known, inferred, and hypothetical. | Lets the buyer audit support strength before relying on the package. |
| Key Findings Quant Synthesis | Summarizes the most decision-relevant findings and their implications for the dossier thesis. | Helps the buyer inspect the argument, evidence posture, and decision logic before relying on the package. |
| Mechanistic Deep Dive | Explains which biological signals matter for interpreting the field and discriminating between programs. | Helps the buyer inspect the argument, evidence posture, and decision logic before relying on the package. |
| Tumor Type Deep Dives | Explains which biological signals matter for interpreting the field and discriminating between programs. | Helps the buyer inspect the argument, evidence posture, and decision logic before relying on the package. |
| Detection and Trigger Design | Summarizes a report component that ties field evidence to the dossier's decision logic. | Helps the buyer inspect the argument, evidence posture, and decision logic before relying on the package. |
| Neoantigen Target Quality | Summarizes a report component that ties field evidence to the dossier's decision logic. | Lets the buyer audit support strength before relying on the package. |
| Immune Response and Microenvironment | Summarizes a report component that ties field evidence to the dossier's decision logic. | Helps the buyer inspect the argument, evidence posture, and decision logic before relying on the package. |
| Manufacturing and Time to Treat | Identifies translational, regulatory, safety, or delivery constraints that shape whether the thesis can be tested. | Helps the buyer inspect the argument, evidence posture, and decision logic before relying on the package. |
| Discovery Trigger Payload Theorem | Summarizes a report component that ties field evidence to the dossier's decision logic. | Helps the buyer inspect the argument, evidence posture, and decision logic before relying on the package. |
| Discovery Two Population | Summarizes a report component that ties field evidence to the dossier's decision logic. | Helps the buyer inspect the argument, evidence posture, and decision logic before relying on the package. |
| Discovery Immunopeptidome Inversion | Summarizes a report component that ties field evidence to the dossier's decision logic. | Helps the buyer inspect the argument, evidence posture, and decision logic before relying on the package. |
| Discovery Market As Experiment | Connects research maturity to competitive position, program strategy, and diligence watchpoints. | Connects research claims to practical diligence and monitoring decisions. |
| Competing Interpretations Adjudicated | Compares alternative readings of the evidence and explains why the dossier weights one interpretation over another. | Helps the buyer inspect the argument, evidence posture, and decision logic before relying on the package. |
Evidence & Decision Workbook
The workbook is the decision engine.
A locked public preview of selected workbook-derived sheets: sheet structure, decision modules, power rows, traceability, and audit posture. Licensed buyers receive the full workbook files.
Read-only workbook preview with clipped values and no formulas. Licensed buyers receive the full Evidence & Decision Workbook with editable assumptions and working files.
Workbook inventory
Delivered workbook sheets.
Full inventories belong on dossier pages, not the homepage. Sheet names below are extracted from the actual workbook file.
| # | Workbook sheet | What it does |
|---|---|---|
| 1 | 1 Guide | Navigation layer for using the workbook, understanding sheet roles, and following the decision package. Public preview exposes Canonical source, Evidence pack. fields and clipped entries such as Claim reconciliation, 154 audited = 90 kept + 64 excluded..,. |
| 2 | 2 Claim Ledger | Claim-by-claim ledger showing verdicts, source support, inference status, and decision relevance. Public preview exposes claim_id, claim_text, report_section, report_page fields and clipped entries such as K01, DYNAMIC trial: ctDNA-guided adjuvant., Key. |
| 3 | 3 Evidence Table | Evidence-verification surface for checking sources, support quality, and the audit trail. Public preview exposes PMID:39930781, PMID, Circulating tumor DNA for., Acta oncologica (Stockholm,. fields and clipped entries such as PMID:39972124, PMID, RNA. |
| 4 | 4 Source-Support Verdicts | Independent check on whether key claims are actually supported by cited sources. Public preview exposes PMID 40055522, DYNAMIC 5-yr, Circulating tumor DNA analysis., supports-exactly (numbers. fields and clipped entries such as PMID 41115959, DYNAMIC-III,. |
| 5 | 5 Source Quality | Summary of source strength, gaps, and areas where conclusions depend on weaker evidence. Public preview exposes Evidence tier, Core-90, Current-signal promotions, Customer-facing total fields and clipped entries such as High, Phase III / mature pivotal RCTs. |
| 6 | 6 Tumor-Type Scorecard | Executable decision surface for classifying programs, risks, gates, or evidence states. Public preview exposes Tumor type, Detection/Trigger, Target Quality, Immune/TME fields and clipped entries such as Melanoma, GO (highest), High shedding, high TMB, hot. |
| 7 | 7 Program-Asset Tracker | Tracks programs, trials, sponsors, or competitive context for diligence and monitoring. Public preview exposes Asset, Sponsor, Modality, Tumor fields and clipped entries such as Intismeran autogene (V940/mRNA-4157), Moderna/Merck, mRNA-LNP personalized. |
| 8 | 8 Platform Comparison | Tracks programs, trials, sponsors, or competitive context for diligence and monitoring. Public preview exposes Platform, Clinical evidence, Target breadth, Mfg speed fields and clipped entries such as mRNA-LNP (personalized), Best clinical evidence. |
| 9 | 9 Five-Axis Scorecard | Executable decision surface for classifying programs, risks, gates, or evidence states. Public preview exposes Program, Detection, Target, Immune/TME fields and clipped entries such as Melanoma — V940+pembro, Evidentiary (surrogate not., Bladder — IMvigor011. |
| 10 | 10 Trial Tracker | Tracks programs, trials, sponsors, or competitive context for diligence and monitoring. Public preview exposes NCT, Title, Phase, Status fields and clipped entries such as NCT00656123, A Safety and Feasibility Study of an., ['PHASE1']. |
| 11 | 11 ctDNA Assay Tracker | Tracks programs, trials, sponsors, or competitive context for diligence and monitoring. Public preview exposes Assay / approach, Type, LOD, Lead time fields and clipped entries such as Signatera (tumor-informed), Bespoke, ~0.01%. |
| 12 | 12 Surrogate-Validity Map | Executable decision surface for classifying programs, risks, gates, or evidence states. Public preview exposes Endpoint, Type, Status, Regulatory position (2026) fields and clipped entries such as ctDNA clearance/persistence, Molecular surrogate, Strong. |
| 13 | 13 Manufacturing Readiness | Release-discipline surface for revisions, unresolved issues, audit findings, and readiness tracking. Public preview exposes Anticipatory manufacture-and-hold, Built at surgery; held, Medium, High (held-dose stability) fields and clipped entries such as. |
| 14 | 14 Regulatory Tracker | Tracks regulatory, endpoint, reimbursement, or qualification requirements that shape testing strategy. Public preview exposes Item, Status / date, Relevance, Source fields and clipped entries such as Signatera CDx (MIBC, atezolizumab), FDA approved May 18,. |
| 15 | 15 Figure Source Map | Traceability surface linking claims, figures, calculations, and workbook outputs back to sources. Public preview exposes figure_id, figure_title, figure_family, section_anchor fields and clipped entries such as Figure 12, fig_quant_forest, Forest plot. |
| 16 | 16 Figure Attempt Ledger | Figure and numeric reproduction log for validating calculations, chart inputs, or displayed values. Public preview exposes Figure #, File, Engine, Attempt status fields and clipped entries such as Figure 12, fig_quant_forest.png, deterministic. |
| 17 | 17 Hypotheses Ledger | Maps hypotheses to evidence state, falsification logic, endpoints, and next-study design. Public preview exposes ID, Tier, Five-axis coupling, Currency (KEEP/UPDATE/NEW) fields and clipped entries such as H1, Flagship, Target Quality x Detection (Coupling.. |
| 18 | 18 Next Studies | Prioritizes next studies that could change the decision, including endpoints and evidence gates. Public preview exposes ID, Question, Design, Primary endpoint fields and clipped entries such as H1, In ctDNA-positive resected disease,., Biomarker-stratified. |
| 19 | 19 Verification & Search Log | Release-discipline surface for revisions, unresolved issues, audit findings, and readiness tracking. Public preview exposes PUBMED, ctDNA AND (surrogate endpoint OR., 15 results, 2026-06 latest-developments search fields and clipped entries such as PUBMED,. |
| 20 | 20 Excluded Claims | Disposition log for rejected, bounded, or quarantined claims so they do not leak into the decision thesis. Public preview exposes Set, Claim (label), Citation, Disposition fields and clipped entries such as beyond_capacity, Excluded 148 — Neoantigens and. |
| 21 | 21 Salvage Ledger | Disposition log for rejected, bounded, or quarantined claims so they do not leak into the decision thesis. Public preview exposes Type, Source, Target section, Basis fields and clipped entries such as Recovered, Excluded 148 — Neoantigens and tumor.,. |
| 22 | CSR. Current-Signal Refresh | Tracks biomarkers or readouts that determine whether the thesis is moving toward testable evidence. Public preview exposes ID, Program / topic, Verified fact, Tag fields and clipped entries such as F-NEW-01, intismeran autogene (V940 / mRNA-4157),. |
| 23 | PWR. Power Calculations | Power-calculation layer for assumptions, endpoint logic, computed sample sizes, and sensitivity checks. Public preview exposes hypothesis_id, study_id, endpoint, test_type fields and clipped entries such as H1, ASSAY-VAX-CLONAL, 18-mo RFS (clonal-only vs. |
| 24 | SB. Score Basis | Explains how scores or ratings were assigned so the decision instrument can be inspected. Public preview exposes Ordinal scale, Where used, 0 / low, 1-2 / mid fields and clipped entries such as ctDNA shedding (0-3), Detection figs, IFC, minimal/near-LOD. |
| 25 | CL. Competitive Landscape | Tracks programs, trials, sponsors, or competitive context for diligence and monitoring. Public preview exposes Company, Asset / platform, Modality, Target / indication fields and clipped entries such as Moderna / Merck, intismeran autogene (V940/mRNA-4157),. |
| 26 | IFC_Input_Template | Executable decision surface for classifying programs, risks, gates, or evidence states. Public preview exposes Evidence completeness, 0-1 (drives MIXED/LOW-CONFIDENCE., guard fields from this sheet. |
| 27 | IFC_Feature_Score | Executable decision surface for classifying programs, risks, gates, or evidence states. Public preview exposes Candidate class, Fit 0-3 (ENTER), Weight (expert-init), Weighted = Fit x Weight fields and clipped entries such as PERSONALIZED-FITS, 1.2,. |
| 28 | IFC_Class_Output | Executable decision surface for classifying programs, risks, gates, or evidence states. Public preview exposes Evidence completeness (ENTER 0-1), 0.8 fields and clipped entries such as Detection adequacy (ENTER adequate /., adequate, Tumor type (ENTER. |
| 29 | IFC_Decision_Rules | Executable decision surface for classifying programs, risks, gates, or evidence states. Public preview exposes Class, Recommended strategy, Primary functional endpoint, Required safety readout fields and clipped entries such as PERSONALIZED-FITS, Full. |
| 30 | IFC_Tumor_Rules | Workbook surface supporting a specific evidence, decision, study-planning, or release-control workflow. Public preview exposes Tumor (documented forms), Tumor-implied modality, Window status, Detection-safety flag fields and clipped entries such as melanoma,. |
| 31 | IFC_Minimum_Assay_Panel | Executable decision surface for classifying programs, risks, gates, or evidence states. Public preview exposes Neoantigen-specific T-cell assay., Immune / endpoint, Preferred fields from this sheet. |
| 32 | IFC_Archetype_Cards | Executable decision surface for classifying programs, risks, gates, or evidence states. Public preview exposes Archetype, Profile, Output class, Matched move fields and clipped entries such as Melanoma, slow relapse, hot, brisk., S>0, clonal, hot,. |
| 33 | IFC_Validation_Log | Executable decision surface for classifying programs, risks, gates, or evidence states. Public preview exposes Functional endpoint, 18-mo RFS / DFS fields and clipped entries such as Calibration, required (reliability across sites), Weights. |
| 34 | IFC_Traceability_Map | Traceability surface linking claims, figures, calculations, and workbook outputs back to sources. Public preview exposes IFC element, Maps to claim/finding, Evidence ID, Figure fields and clipped entries such as Window-Solvency S = L-(V+I), finding-window;. |
| 35 | TC. Traceability Certificate | Traceability surface linking claims, figures, calculations, and workbook outputs back to sources. Public preview exposes claim_id, report_section, report_page, claim_text fields and clipped entries such as K01, Key Findings / Quantitative Evidence, see PDF. |
| 36 | VR. Version Registry | Release-discipline surface for revisions, unresolved issues, audit findings, and readiness tracking. Public preview exposes v2.1 (REV-2 hardening), 2026-06-15, Audit remediation: full §32 Claim., Claude (Opus 4.8) fields and clipped entries such as v2.0. |
| 37 | AI. Audit Issues Log | Release-discipline surface for revisions, unresolved issues, audit findings, and readiness tracking. Public preview exposes ID, Issue, Status, Resolution fields and clipped entries such as A-1, Workbook genuinely executable?, RESOLVED. |
Power-calculated next studies
Power calculations are the execution bridge.
Power calculations are planning-grade research calculations for endpoint logic, assumptions, sample size, budget, and timeline. They do not prove hypotheses or constitute clinical protocol.
| Hypothesis | Primary endpoint | Test | Effect | α | Power | Computed n | Design n |
|---|---|---|---|---|---|---|---|
| H1 | 18-mo RFS (clonal-only vs full personalized vaccine, ctDNA+) | survival | 0.6 | 0.05 | 0.80 | 269 | 269 |
| H2 | 12-mo RFS non-inferiority (shared mKRAS vs personalized, ctDNA+ KRAS-... | noninferiority | 0.3 | 0.05 | 0.80 | 260 | 260 |
| H3 | Week-24 ctDNA clearance (immune-non-responder adaptive randomization) | twoprop | 0.5 | 0.05 | 0.80 | 93 | 93 |
| H4 | Treatment-by-stratum interaction on RFS (Cox/logistic interaction term) | interaction | 0.45 | 0.05 | 0.80 | 650 | 650 |
| H5 | Week-12 T-cell response: primary contrast sequential (C) vs concurren... | twoprop | 0.5 | 0.03 | 0.80 | 70 | 70 |
Release audit discipline
Audit posture is part of the product.
Public pages do not publish exact audit scores. They should state the release discipline, revision posture, and limitations without implying peer review or validated clinical guidance.
Research-use decision package
Not medical advice, clinical guidance, investment advice, or a clinical protocol.
Known / inferred / hypothetical
The package separates cited evidence from inference and frontier hypothesis generation.
Audit-gated and revision-controlled
Adversarial audit checks source support, formulas, figures, limitations, and release readiness.
Buy this dossier
Full decision package — 115-page report + 37-sheet workbook
Buy now
- Decision research report (115 pages, PDF)
- Evidence & Decision Workbook (37 sheets, .xlsx) — claims, source-support verdicts, power calculations, traceability, and audit log
- Live, editable power-calculated next studies
$3,500$5,500Launch price